Verici Dx (LON:VRCI) Shares Down 18.2% – Here’s Why

Verici Dx plc (LON:VRCI)’s stock price was down 18.2% during trading on Thursday . The company traded as low as GBX 2.25 ($0.03) and last traded at GBX 2.25 ($0.03). Approximately 624,617 shares were traded during mid-day trading, a decline of 29% from the average daily volume of 884,824 shares. The stock had previously closed at GBX 2.75 ($0.04).

Verici Dx Stock Performance

The company has a debt-to-equity ratio of 4.64, a quick ratio of 8.49 and a current ratio of 4.54. The stock has a market cap of £7.59 million, a PE ratio of -1.45 and a beta of 1.59. The company’s 50-day moving average price is GBX 3.16 and its two-hundred day moving average price is GBX 3.88.

Verici Dx Company Profile

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.